INCY News and Press, Incyte Corporation From 04/06/24

2024-04-06 11:54:38 ET A U.S. district court jury has found a former pharmaceutical company executive liable for insider trading allegations brought by the Securities and Exchange Commission (SEC).... Read the full article on Seeking Alpha For further details see: Jury sides...

2024-04-04 11:12:55 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli...

2024-04-01 11:11:03 ET More on S&P 500 Index: China PMI Is Better Than Expected But The Greenback Still Rises Above CNY7.23 The March Labor Report Preview: The Cracks Are Deepening S&P 500 Closes Its Best Quarter Since 2019 At Record High The least sh...

2024-04-01 09:35:23 ET More on Incyte Incyte: A Potential GARP Superstar Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation FDA accepts Incyte application for graft-versus-host disease ...

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria Incyte (Nasdaq:INCY) (“I...

Incyte (Nasdaq:INCY) announced today that it granted equity inducement awards to Matteo Trotta, the Company’s new Executive Vice President and General Manager of U.S. Dermatology, pursuant to the Company’s 2024 Inducement Stock Incentive Plan. The awards were approved by the compens...

2024-03-23 13:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-13 11:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 13:07:11 ET More on S&P 500 Index: Japan's Q4 '23 Contraction Revised Away, Helping Keep Yen Bid S&P 500: 'Everything' Is Overbought, Not Just Semis And Nvidia S&P 500: A Significant Change - Week Starting 11th March (Technical Analysis) ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis (PN) Results presented as a late-breaking oral presentation at the American Academy of ...